Evidence map›Paper›PMID 27255479›Full record

ArticleWorld journal of urology2017

Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.

Hong Hu, Xiajuan Yao, Xiangcheng Xie, Xia Wu, Chuanming Zheng, Wenkai Xia, Shenglin Ma

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 138 citations in OpenAlex.

  1. Pooled it
  2. Sarcopenia predicts prognosis of patients with renal cell carcinoma: A systematic review and meta-analysis.International braz j urol : official journal of the Brazilian Society of Urology
    Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Role of Platelet to Lymphocyte Ratio (PLR) in Predicting Early Treatment Response in Diffuse Large B Cell Lymphoma.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Hong HuDepartment of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, 163 Shoushan Road, Jiangyin, 214400, Jiangsu, China.
Xiajuan YaoDepartment of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, 163 Shoushan Road, Jiangyin, 214400, Jiangsu, China.
Xiangcheng XieDepartment of Nephrology, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, Hangzhou, Zhejiang, China.
Xia WuDepartment of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, 163 Shoushan Road, Jiangyin, 214400, Jiangsu, China.
Chuanming ZhengDepartment of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhengjiang, China.
Wenkai XiaDepartment of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, 163 Shoushan Road, Jiangyin, 214400, Jiangsu, China. xiawenkai23@163.com.
Shenglin MaDepartment of Oncology, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, 261 Huansha Road, Hangzhou, 310006, Zhejiang, China. mashenglin@medmail.com.cn.
Hangzhou First People's Hospital · CNJiangyin People's Hospital · CNSoutheast University · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging evidences indicate that inflammation plays a crucial role in carcinogenesis and tumor progression. Inflammatory response biomarkers are recognized as promising prognostic factors for improving predictive accuracy in renal cell carcinoma (RCC). We aimed to evaluate the prognostic significance of preoperative neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR) and serum C-reactive protein (CRP) in RCC.

methods484 surgical RCC patients were enrolled from 2006 to 2010 in this study. Receiver operating curve (ROC) was applied to assess the optimal cutoff levels for four biomarkers, and the prognostic values were determined by Kaplan-Meier curve, univariate and multivariate COX regression models. The predictive accuracy was evaluated by concordance index (c-index).

resultsThe median follow-up duration after surgical resection was 36 months. The optimal cutoff levels were 2.78 for NLR, 2.05 for dNLR, 185 for PLR and 5.1 for CRP by ROC curves analysis. Elevated NLR, dNLR, PLR and CRP were significantly correlated with worse overall survival (OS). Multivariate analysis showed that elevated NLR was an independent risk factor for OS, and NLR was superior to dNLR, PLR and CRP based on hazard ratio (HR 2.10, 95 % CI 1.21-3.64, P = 0.008). Additionally, the nomogram could more effectively work in predicting OS (c-index: 0.749) in surgical RCC patients.

conclusionPre-operation NLR can be considered as a potential prognostic biomarker in patients with RCC who underwent surgical resection.

Indexed as

Blood PlateletsLymphocytesNeutrophilsAdultAgedAged, 80 and overCarcinoma, Renal CellC-Reactive ProteinFemaleHumansKidney NeoplasmsLeukocyte CountMaleMiddle AgedPlatelet CountPreoperative PeriodC-Reactive ProteinNeutrophil-to-lymphocyte ratioPrognosisRenal cell carcinomaSurvival

Identifiers

PMID27255479
OpenAlexW2414218266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.